Microfluidic Platform for NAFLD Biomarker Discovery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic approaches for non-alcoholic fatty liver disease (NAFLD) are invasive, costly, and inefficient, lacking effective biomarkers for early detection and progression monitoring, which hinders timely intervention and treatment.
Innovation Solution
A preclinical microfluidic platform, or microphysiological system (MPS), is developed to study druggable targets and drug efficacy, integrating metabolomics and transcriptomics for noninvasive biomarker discovery and stratified medicine development, recreating human liver and adipose tissue environments for high-throughput experimentation and systems biology analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If liver biopsy is used for NAFLD diagnosis and monitoring, then diagnostic accuracy is improved, but invasiveness and cost increase
Solution Approach 1:
The patent creates a microphysiological system that copies liver tissue architecture and function in vitro, allowing disease modeling and biomarker discovery without requiring invasive human biopsies. The system replicates liver sinusoids, hepatocytes, and Kupffer cells to simulate NAFLD pathophysiology
Solution Approach 2:
The patent uses microfluidic devices as an intermediary system between in vivo human liver and in vitro analysis. The device captures circulating exosomes from blood samples and processes them through controlled experimental conditions to extract biomarker information, serving as a bridge between clinical sampling and diagnostic analysis
2Loss of information
If long-term patient cohorts are monitored for NAFLD biomarker discovery, then disease progression understanding is improved, but study duration and confounding factors increase
Solution Approach 1:
The patent performs preliminary disease modeling in the microphysiological system by inducing metabolic dysfunction and NAFLD-like conditions in controlled timeframes (weeks rather than decades). This accelerates the disease progression process that would normally take decades in human patients, allowing rapid biomarker discovery without long-term cohort follow-up
Solution Approach 2:
The patent changes the timescale parameter by using primary human cells in a controlled microenvironment that accelerate disease-relevant phenotypic changes. The system induces metabolic dysfunction and disease progression in weeks rather than decades through controlled nutritional and metabolic conditions
3Ease of operation
If traditional cell culture systems are used for drug screening, then ease of operation is improved, but physiological relevance decreases
Solution Approach 1:
The patent implements local quality by creating distinct microenvironments within the device that replicate specific liver tissue zones (periportal vs. perivenous). Different cell types are positioned in anatomically correct locations with appropriate oxygen and nutrient gradients, maintaining physiological relevance while remaining operationally manageable
Data Source
AI summary
A method for developing stratified medicine for nonalcoholic fatty liver disease (NAFLD includes obtaining a microphysiological system (MPS) comprising a liver tissue cytoarchitecture, adipose tissue, or both. The method includes inducing metabolic dysfunction representing NAFLD in the liver or adipose tissue of the MPS. The method includes generating, based on inducing the metabolic dysfunction, transcriptomics data for the MPS. The method includes applying a drug to the MPS using a dosing regimen. The method includes monitoring changes in the transcriptomics data based on applying the drug. The method includes generating a model relating the changes in the transcriptomics data to the dosing regimen of the drug.